Elosulfase alfa (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Elosulfase alfa" in English language version.

refsWebsite

Global rank English rank

3web.archive.org

1^st place

1^st place

4^th place

4^th place

2^nd place

2^nd place

447^th place

338^th place

3,984^th place

2,622^nd place

low place

8,252^nd place

8,096^th place

low place

doi.org

Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. (November 2014). "Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study". Journal of Inherited Metabolic Disease. 37 (6): 979–90. doi:10.1007/s10545-014-9715-6. PMC 4206772. PMID 24810369.
Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. (February 2015). "Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial". Molecular Genetics and Metabolism. 114 (2): 178–85. doi:10.1016/j.ymgme.2014.08.012. PMID 25284089.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

fda.gov

"FDA approves Vimizim to treat rare congenital enzyme disorder". Food and Drug Administration. Feb 14, 2014. Archived from the original on January 27, 2017. Retrieved December 16, 2019.

health.gov.au

"Providing $400,000 life-saving drug to Australian kids with rare disease. The Australian Government will provide a life-saving treatment to Australian patients who have a rare medical condition known as Morquio A Syndrome, at no cost. The Hon Greg Hunt MP. Minister for Health. 15 June 2017". Archived from the original on 14 April 2018. Retrieved 13 September 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. (November 2014). "Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study". Journal of Inherited Metabolic Disease. 37 (6): 979–90. doi:10.1007/s10545-014-9715-6. PMC 4206772. PMID 24810369.
Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. (February 2015). "Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial". Molecular Genetics and Metabolism. 114 (2): 178–85. doi:10.1016/j.ymgme.2014.08.012. PMID 25284089.

ncbi.nlm.nih.gov

Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. (November 2014). "Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study". Journal of Inherited Metabolic Disease. 37 (6): 979–90. doi:10.1007/s10545-014-9715-6. PMC 4206772. PMID 24810369.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

tijd.be

"BioMarin moet verder levensreddend middel leveren aan patiënte" [BioMarin must continue to provide life-saving drug to patient]. www.tijd.be (in Dutch). De Tijd. 26 June 2019. Archived from the original on 27 June 2019. Retrieved 26 June 2019.

web.archive.org

"FDA approves Vimizim to treat rare congenital enzyme disorder". Food and Drug Administration. Feb 14, 2014. Archived from the original on January 27, 2017. Retrieved December 16, 2019.
"Providing $400,000 life-saving drug to Australian kids with rare disease. The Australian Government will provide a life-saving treatment to Australian patients who have a rare medical condition known as Morquio A Syndrome, at no cost. The Hon Greg Hunt MP. Minister for Health. 15 June 2017". Archived from the original on 14 April 2018. Retrieved 13 September 2018.
"BioMarin moet verder levensreddend middel leveren aan patiënte" [BioMarin must continue to provide life-saving drug to patient]. www.tijd.be (in Dutch). De Tijd. 26 June 2019. Archived from the original on 27 June 2019. Retrieved 26 June 2019.